BeOne Medicines reported a robust first-half performance for the six months ended 30 June 2026, driven by surging global demand for flagship BTK inhibitor BRUKINSA and continued expansion of its oncology portfolio.

Revenue and Profitability • Total revenue advanced 32.3% year-on-year to USD 3.22 billion. • Product sales contributed USD 3.17 billion, up 31.4%; other revenue (mainly royalties from Amgen and Novartis agreements) rose 133.9% to USD 51.39 million. • Net income reached USD 464.36 million, a 385.8% jump from USD 95.59 million a year earlier, lifting basic EPS to USD 0.32 (H1 2025: USD 0.07). • Gross profit widened to USD 2.88 billion, with gross margin improving to 89.2% from 86.3% on a richer sales mix of BRUKINSA and operational efficiencies.

Sales Breakdown • BRUKINSA: USD 2.34 billion, +34.5%, buoyed by U.S. sales of USD 1.65 billion (+32.6%) and European revenue of USD 378.0 million (+41.9%). • TEVIMBRA: USD 434.76 million, +19.2%. • In-licensed Amgen products (XGEVA, BLINCYTO, KYPROLIS): combined USD 297.11 million, led by 28.1% growth in XGEVA to USD 194.42 million. • China generated USD 978.00 million (+17.5%), the U.S. USD 1.70 billion (+34.4%), Europe USD 402.75 million (+48.6%), and Rest of World USD 141.30 million (+109.3%).

Cost Structure • Research & Development expense rose 14.6% to USD 1.15 billion, reflecting pipeline expansion and Amgen co-development funding. • Selling, General & Administrative costs increased 15.2% to USD 1.15 billion amid global commercial build-out. • Operating expenses represented 71.6% of revenue versus 82.4% a year earlier, supporting a five-fold rise in operating income to USD 574.95 million.

Cash Flow and Balance Sheet • Operating cash flow turned in USD 664.16 million (H1 2025: USD 307.68 million); free cash flow stood at USD 595.89 million. • Cash and cash equivalents totaled USD 5.10 billion at period-end, up from USD 4.55 billion at FY 2025. • Total debt was USD 1.07 billion; gearing ratio eased to 20.7% (FY 2025: 23.4%). • The company projects sufficient liquidity to fund operations and investment plans for at least the next 12 months.

Product & Pipeline Highlights • Positive Phase 3 data for BRUKINSA plus rituximab in first-line mantle cell lymphoma. • FDA accelerated approval of BEQALZI (sonrotoclax) for relapsed/refractory mantle cell lymphoma. • FDA clearance of TEVIMBRA in combination with zanidatamab and chemotherapy for first-line HER2-positive gastric and related cancers. • Announced a multi-part collaboration with Revolution Medicines targeting RAS(ON) inhibitors and expanded its New Jersey manufacturing site with a USD 300 million investment.

Capital Expenditure & Commitments • H1 2026 capex reached USD 68.27 million, mainly for the Hopewell manufacturing and R&D facility; construction in progress there totaled USD 95.76 million. • Outstanding purchase commitments stood at USD 262.82 million, while co-development funding obligations to Amgen had fallen to USD 12.53 million.

Dividend No interim dividend was declared.

Governance Updates The board appointed Dr. Felix J. Baker (non-executive), Ms. Elizabeth F. Mooney (independent non-executive) and Dr. Charles L. Sawyers (independent non-executive) on 11 June 2026, coinciding with the departures of three directors. Audit, Compensation, and Nominating committees were re-constituted accordingly.

Outlook Management reiterated its strategy to leverage strong cash reserves, a diversified oncology pipeline, and manufacturing expansion to sustain global growth, with BRUKINSA, TEVIMBRA and newly approved BEQALZI underpinning revenue momentum in the second half of 2026.